FACIT
VC Fund
Toronto, Canada
FACIT is a commercialization venture firm that builds companies with entrepreneurs to accelerate oncology innovation, with a portfolio that has attracted over $850 million in investment to Ontario. Blending industry experience, capital and the unsurpassed clinician-scientist network of its strategic partner the Ontario Institute for Cancer Research(OICR), FACIT capitalizes on the province's investment in research and healthcare to the benefit of the local economy and patients worldwide.
- Total investments:
- 31
- Last investment:
- Lead investor:
- 29%
- Last fund:
Last updated:
For AI agents: llms.txt
Industries FACIT invests in
Stages FACIT invests in
Countries FACIT invests in
Round sizes
Round size
- Seed
- $1.5M–$8M
- Series A
- $11M–$35M
Investment Focus
Industry
- Biotechnology 13 (42%)
- Health Care 8 (26%)
- Medical Device 6 (19%)
- Medical 5 (16%)
- Life Science 5 (16%)
Stage
- Seed 15 (48%)
- Pre-Seed 2 (6%)
- Series A 2 (6%)
- Series B 2 (6%)
- Funding Round 2 (6%)
Country
- Canada 21 (68%)
- United States 3 (10%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Esphera SynBio operates as a biotechnology company. Esphera SynBio provides practitioners of synthetic biology for the treatment and prevention of disease. | $2M / Seed / Jan 07, 2025 | ||
| Hyivy Health creates an intelligent and holistic pelvic rehabilitation device for the 1 in 3 women worldwide who will experience a pelvic health complication in their lifetime. Our device provides the first quantifiable data set on the pelvic floor and 3 different therapies from multiple sensors and mechanical functions to help keep track ofprogress, adapt treatment plans and provide more effective, comfortable rehab experiences. | $1.5M / Seed / Sep 24, 2024 | ||
| Radiant Biotherapeutics is a revolutionary antibody platform company leading the new frontier of multi-valent, multi-specific therapeutics to deliver transformative therapies for patients. | $35M / Series A / Sep 11, 2024 | ||
| HDAX Therapeutics is pioneering next-gen precision therapeutics for cardiovascular and neurological diseases by targeting their root causes to enhance patient outcomes. | $3.2M / Seed / Sep 05, 2024 | ||
| Tenomix mission is to develop novel technologies that target inefficiencies in the pathology workflow optimize cancer care and reduce healthcare costs | $1.6M / Seed / Mar 01, 2024 | ||
| Radiant Biotherapeutics is a revolutionary antibody platform company leading the new frontier of multi-valent, multi-specific therapeutics to deliver transformative therapies for patients. | $8M / Seed / Apr 25, 2023 | ||
| CTRL Therapeutics operates a biotechnology company that researches on cell therapy development and treatment. It is based in Toronto, Canada. | $10M / Seed / Apr 10, 2023 | ||
| HDAX Therapeutics is pioneering next-gen precision therapeutics for cardiovascular and neurological diseases by targeting their root causes to enhance patient outcomes. | Seed / Sep 28, 2022 | ||
| Nanology Labs has designed and is developing Manganescan®, a novel theranostic agent (MRI contrast agent/Radio-sensitizer) that allows detection of brain tumors at early stages using MRI. Simultaneously, it sensitizes cancer cells which improves radiation therapy outcomes. The agent is 3x more sensitive than current Gadolinium contrast agents(GBCAs), can cross the blood brain barrier and enables early and precise detection and targeting of brain cancer. | $3M / Seed / May 17, 2021 | ||
| Replica Analytics develops unique technologies for generating privacy protective synthetic data that maintains the statistical properties of real data | $1M / Seed / Jun 24, 2020 | ||
| See all 31 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does FACIT invest in?
FACIT invests primarily in Biotechnology, Health Care and Medical Device startups, most often at Seed and Pre-Seed stage. Most of the 31 investments tracked by Shizune back companies in Canada. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does FACIT invest in?
FACIT typically joins rounds of $1.5M–$8M at Seed and $11M–$35M at Series A. These are whole funding-round sizes, not FACIT's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds FACIT took part in.
When did FACIT last invest?
The most recent investment recorded for FACIT closed in Jan 2025. Shizune tracks 31 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
